Bristol Myers Squibb outperformed the broader market in the latest session with a 1.22% gain, even as it faces financial ...

Sildenafil citrate during labor did not improve perinatal outcomes potentially related to intrapartum hypoxia despite ...

The latest trading day saw Bristol Myers Squibb (BMY) settling at $49, representing a +1.22% change from its previous close.

This was the stock's second consecutive day of gains.

Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of DirectorsDavid Shook, MD appointed as Chief ...

Here are seven new shortages and discontinuations, according to drug supply databases from the FDA and the American Society of Health-System Pharmacists. Editor’s note: The drugs listed are in alphabe ...

When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. | After ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

ASCO 2025 delivered pivotal updates. In this article, we discuss 8 of the more interesting abstracts from an investment ...

Mergers and Acquisitions (M&A) have picked up significant pace in 2025 in the pharma/biotech sector after a passive run in 2024. The recent spree of acquisitions signifies a focus on portfolio ...

A groundbreaking lung cancer screening project co-led by the University of Kentucky Markey Cancer Center and the University ...

Giving patients more direct control over their healthcare data is a frequent talking point among healthcare leaders. | The ...